Acute Myeloid Leukemia Cell Therapy Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs and Forecast, 2031
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Acute Myeloid Leukemia Market Report Overview
The AML market value for the 15 markets (15M) was $3.1 billion in 2021. Acute myeloid (or myelogenous or myelocytic) leukemia (AML) is a malignancy of the hematopoietic system caused by the abnormal proliferation or differentiation of myeloid progenitors in the bone marrow and peripheral blood. AML is relatively rare and has a poor prognosis, particularly in elderly patients. The first approval for cell therapy drugs is anticipated in 2023, which is expected to positively impact the market growth.
The AML market research report includes an assessment of the disease epidemiology and 10-year patient-based forecast (PBF) across the 8MM for marketed and pipeline therapies with established mechanisms of action and cell therapies by class, including early to late clinical stage pipeline products, with a launch date assessment by market for acute myeloid leukemia (AML). The report also analyzes the clinical and commercial landscapes of AML, with pricing assumptions based on currently marketed products by class of cell therapies, accompanied by a transparent forecast methodology.
Market Size (2021 in 15M) | $3.1 Billion |
Key Regions | North America, APAC, Europe, and The Middle East |
Future Players | Bellicum Pharmaceuticals, Orca Biosystems, University Health Network; Ozmosis Research Inc, Vor BioPharma Inc, MediGene AG, Chongqing Precision Biotech Co Ltd, PersonGen BioTherapautics (Suzhou) Co. Ltd, Anhui Provincial Hospital, Zhejiang University, Shanghai YaKe Biotechnology Co. Ltd, Tianjin First Central Hospital, Guangzhou Bio-gene Technology Co. Ltd |
AML Market Drivers
Anticipated market approval for allogeneic, unclassified “other” cell therapies in 2023 will mark the beginning of a market for cell therapies in AML, which currently has no approved cell therapies. Even though fewer patients are expected to be treated with CAR-T cells compared to other cell therapies, the high anticipated price of CAR-T cells will translate to the highest revenue among cell therapy products.
Furthermore, there is also a very high level of unmet needs in the R/R setting. The frequent use of stem cell transplants that promotes the development of stem cell transplant-augmenting or replacement products, will also drive the market growth.
To know more about the drivers of the AML market, download a free report sample
Acute Myeloid Leukemia Market Unmet Needs
AML presents a few unmet needs that can be well addressed by cell therapies. The most important of these are improved outcomes after transplant, and treatments in the second line and beyond. Many non-classified cell therapies aim to fill the gap in outcomes left by allogeneic stem cell transplants, and GlobalData views this as an important market opportunity.
To know more about the unmet needs in the AML market, download a free report sample
AML Market Segmentation by Regions
The key regions in the AML market are North America, APAC, Europe, and the Middle East. North America had the highest share in 2021.
Acute Myeloid Leukemia Market Analysis by Regions, 2021 (%)
For more regional insights on the Acute Myeloid Leukemia market, download a free report sample
Acute Myeloid Leukemia Market - Competitive Landscape
Some of the future players in the AML market are Bellicum Pharmaceuticals, Orca Biosystems, University Health Network; Ozmosis Research Inc, Vor BioPharma Inc, MediGene AG, Chongqing Precision Biotech Co Ltd, PersonGen BioTherapautics (Suzhou) Co. Ltd, Anhui Provincial Hospital, Zhejiang University, Shanghai YaKe Biotechnology Co. Ltd, Tianjin First Central Hospital, Guangzhou Bio-gene Technology Co. Ltd. Bellicum Pharmaceuticals is the leading sponsor of cell therapy trials in AML, followed by Orca Bio.
For more insights on companies in the AML market, download a free report sample
Scope
- This report includes disease epidemiology, a 10-year patient-based forecast for marketed and pipeline therapies with established mechanisms of action, and cell & gene therapies by class, including early- to late clinical-stage pipeline products with launch date assessment by the 8MM market.
- The forecast includes 8 countries for the period of 2021-2031
- Seven markets are extrapolated, obtaining a 15-market value for all AML therapeutics
Reasons to Buy
The report will help to understand:
- What is the target patient pool for cell & gene therapies in each cancer indication?
- Which patient groups are more likely to receive these therapies?
- What does the cell & gene therapy clinical stage pipeline look like in each cancer indication?
- What is the anticipated breakdown between autologous and allogeneic cell therapies?
- When will cell & gene therapies launch in each market?
- What is the total market value projected for the forecast end, in 2031?
Gamida Cell
Marker Therapeutics
Table of Contents
Frequently asked questions
-
What was the AML market size in the 15M in 2021?
The AML market value for the 15 markets (15M) was $3.1 billion in 2021.
-
What are the key regions in the AML market?
The key regions in the AML market are North America, APAC, Europe, and the Middle East.
-
Which region has the highest share in the AML market?
North America has the highest share in the acute myeloid leukemia market.
-
Who are the future players in the AML market?
Some of the future players in the AML market are Bellicum Pharmaceuticals, Orca Biosystems, University Health Network; Ozmosis Research Inc, Vor BioPharma Inc, MediGene AG, Chongqing Precision Biotech Co Ltd, PersonGen BioTherapautics (Suzhou) Co. Ltd, Anhui Provincial Hospital, Zhejiang University, Shanghai YaKe Biotechnology Co. Ltd, Tianjin First Central Hospital, Guangzhou Bio-gene Technology Co. Ltd.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.


